As Chief Audit Officer of Novartis, Teresa and her team provide risk-based assurance and advice on key strategic topics to the Board and management, acting as a key partner to the organization to help ...

We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Innovation enables faster adaptation and response to changes, promotes growth, and distinguishes a company from its competitors. The foundation of breakthrough innovations and good science are diverse ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult ...

What is Novartis Managed Access? There are instances where a patient has a serious or life-threatening disease or condition, for which all currently available treatment options have been exhausted and ...

Careers at Novartis in Slovenia. At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to ...

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease ...

Key Inclusion Criteria: * 18 years and older at time of signing consent * Patients with primary or secondary wAIHA documented by positive direct antiglobulin test specific for anti-IgG or anti-IgA, ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Our significant investment in research and development underpins our commitment to ...

Novartis may provide external funding to legitimate organizations in the interest of driving its mission to improve healthcare, advance scientific/medical knowledge or support the communities where ...

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ...